Business NewsPR NewsWire • Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

BASEL, Switzerland, Sept. 12, 2019 /PRNewswire/ -- Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized,...

View More : https://www.prnewswire.com:443/news-releases/strekin-ag-announces-completion-of-patient-recruitment-in-the-restore-phase...
Releted News by prnewswire
Strekin AG termina la reclutación de pacientes para el estudio clínico de STR001
Strekin AG anuncia conclusión de reclutamiento en el estudio clínico RESTORE de fase 3 del STR001
Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001
Evergent integrates its AI-driven Offer Management solution with Microsoft Azure AI to Maximize Subscriber Retention
Medical Tourism Market Value to Hit $30 Billion by 2025: Global Market Insights, Inc.